China SXT Pharmaceuticals, Inc. (SXTC) Key Metrics
SXTC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $673,237
- Enterprise value
- −$23.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.6
- Price / book
- 0.1
- EV / EBITDA
- 7.1
- Dividend yield
- —
- Beta
- 1.86
SXTC key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsSXTC returns How much profit the business earns on the capital it uses.
Return on equity−5.0 pts
−27.5%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets−7.2 pts
−22.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow margin−239.7 pts
−374.5%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover−51.1%
0.04
FY2026 · hover or tap a bar for each year
FY2017FY2026
SXTC financial health Debt, liquidity and how easily interest is covered.
Debt / equity−40.8%
0.04
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt−$9.9M
−$27.1M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio+124.0%
7.93
FY2026 · hover or tap a bar for each year
FY2017FY2026
Interest coverage
-113.1
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets−29.0%
0.03
FY2026 · hover or tap a bar for each year
FY2017FY2026
SXTC efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+533 days
873 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days of inventory+559 days
777 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding+16 days
340 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle+1,076 days
1,310 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue−0.1 pts
0.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
SXTC returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SXTC debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SXTC cash returned to shareholders
DividendsBuybacksFree cash flow
SXTC key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $134.40 | $29,938.80 | $161,280.00 | $680,640.00 | $13,440,000.00 | $88,320,000.00 | $107,539,200.00 | $1,309,440,240.00 | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −27.5% | −22.5% | −21.7% | −38.1% | −35.4% | −21.7% | −100.3% | 21.4% | 46.2% | 91.3% |
| Return on invested capital (ROIC) | — | — | −71.1% | −69.6% | −57.3% | −30.2% | −15.6% | 38.6% | 45.8% | 72.8% |
| Return on assets (ROA) | −22.0% | −14.8% | −11.8% | −18.8% | −16.8% | −9.8% | −52.5% | 12.3% | 18.1% | 20.2% |
| Return on tangible assets | −17.9% | −15.3% | −13.4% | −20.1% | −17.1% | −8.0% | −47.5% | 8.8% | 15.6% | 22.0% |
| Free cash flow margin | −374.5% | −134.8% | −100.3% | −7.7% | −93.6% | −29.5% | 10.2% | −5.3% | 12.4% | 2.2% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | 0.16 | 1.62 | 0.25 |
| Financial health | ||||||||||
| Total debt | $1.1M | $983,877 | $2.6M | $3.8M | $10.7M | $43,414 | $6.7M | $2.8M | $385,121 | $302,168 |
| Cash & short-term investments | $28.2M | $18.1M | $12.1M | $17.4M | $15.5M | $13.3M | $7.3M | $9.1M | $560,252 | $65,570 |
| Net debt | −$27.1M | −$17.1M | −$9.4M | −$13.6M | −$4.8M | −$13.3M | −$563,156 | −$6.3M | −$175,131 | $236,598 |
| Debt / equity | 0.04 | 0.06 | 0.19 | 0.26 | 0.65 | 0.00 | 0.72 | 0.25 | 0.12 | 0.16 |
| Debt / assets | 0.03 | 0.05 | 0.11 | 0.13 | 0.32 | 0.00 | 0.31 | 0.16 | 0.05 | 0.06 |
| Net debt / EBITDA | — | — | — | — | — | — | — | −3.21 | −0.10 | 0.14 |
| Current ratio | 7.93 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | 1.37 |
| Quick ratio | 7.25 | 3.40 | 1.51 | 1.31 | 1.25 | 1.20 | 1.53 | 2.31 | 1.11 | 1.09 |
| Interest coverage | -113.1 | -4.1 | -4.6 | -11.8 | -141.4 | -1.4 | -0.4 | 342.0 | — | 39.7 |
| Working capital | $30.2M | $15.3M | $5.3M | $5.0M | $5.3M | $4.7M | $7.4M | $9.3M | $1.7M | $1.3M |
| Invested capital | $2.7M | −$1.7M | $4.5M | $1.1M | $11.6M | $2.7M | $8.8M | $4.8M | $3.1M | $2.1M |
| Tangible asset value | $29.7M | $15.4M | $13.9M | $14.7M | $16.4M | $15.9M | $9.4M | $11.0M | $3.2M | $1.8M |
| Net current asset value | $29.5M | $15.1M | $5.0M | $4.7M | $5.3M | $4.6M | $7.3M | $9.2M | $1.7M | $1.3M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $2.4M | — | — |
| Share buybacks (net) | — | — | — | — | — | — | — | $0 | — | — |
| Dividend payout ratio | — | — | — | — | — | — | — | 154.8% | — | — |
| Capex / revenue | 0.0% | 0.1% | 0.4% | 3.6% | 2.4% | 1.9% | 7.9% | 8.7% | 15.0% | 3.8% |
| Capex / operating cash flow | — | — | — | — | — | — | 43.5% | 255.1% | 54.7% | 63.6% |
| Capex / depreciation | 0.00 | 0.02 | 0.03 | 0.28 | 0.20 | 0.27 | 1.23 | 3.37 | 8.12 | 1.88 |
| Stock-based compensation / revenue | 494.6% | 0.0% | 18.3% | 28.1% | 89.7% | 26.6% | 110.2% | 0.0% | 0.0% | — |
| R&D / revenue | 16.7% | 11.0% | 9.6% | — | — | — | — | — | — | — |
| SG&A / revenue | 664.5% | 158.4% | 136.7% | 306.0% | 247.5% | 105.4% | 78.4% | 40.5% | 25.2% | 14.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 873.3 | 340.3 | 254.7 | 436.3 | 780.9 | 703.4 | 550.8 | 230.2 | 185.1 | 208.2 |
| Days of inventory on hand | 776.5 | 217.6 | 178.1 | 188.8 | 260.5 | 165.0 | 141.1 | 172.9 | 115.3 | 194.4 |
| Days payables outstanding | 339.8 | 323.9 | 352.8 | 337.7 | 397.1 | 319.9 | 269.2 | 311.2 | 185.2 | 294.9 |
| Cash conversion cycle (days) | 1,310.0 | 234.0 | 79.9 | 287.4 | 644.3 | 548.5 | 422.7 | 92.0 | 115.1 | 107.6 |
| Receivables turnover | 0.42 | 1.07 | 1.43 | 0.84 | 0.47 | 0.52 | 0.66 | 1.59 | 1.97 | 1.75 |
| Payables turnover | 1.07 | 1.13 | 1.03 | 1.08 | 0.92 | 1.14 | 1.36 | 1.17 | 1.97 | 1.24 |
| Inventory turnover | 0.47 | 1.68 | 2.05 | 1.93 | 1.40 | 2.21 | 2.59 | 2.11 | 3.17 | 1.88 |
| Asset turnover | 0.04 | 0.08 | 0.07 | 0.06 | 0.08 | 0.17 | 0.26 | 0.56 | 1.07 | 0.83 |
| Average receivables | $2.6M | $1.6M | $1.3M | $2.4M | $5.6M | $9.2M | $7.8M | $4.4M | $3.6M | $2.8M |
| Average payables | $827,973 | $1.2M | $1.3M | $1.4M | $1.5M | $1.7M | $1.8M | $2.0M | $1.8M | $2.1M |
| Average inventory | $1.9M | $818,905 | $670,506 | $799,547 | $963,768 | $876,232 | $950,342 | $1.1M | $1.1M | $1.4M |
| Intangibles / total assets | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.3% | 0.8% | 0.8% |
Computed from SXTC's annual financial statements (latest annual report filed July 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SXTC valuation and financial ratios
China SXT Pharmaceuticals earned a return on equity of −27.5% in fiscal 2026. It ended the year with $1.1 million of debt and $28.2 million in cash and short-term investments, a net cash position of $27.1 million.
See the SXTC income statement, the SXTC chart for price history, or the SXTC stock overview for the latest quote and news.
SXTC key metrics FAQ
What is China SXT Pharmaceuticals's return on equity?
China SXT Pharmaceuticals's return on equity (ROE) was −27.5% in fiscal 2026: net income of -$6.2 million on average shareholders' equity of $22.6 million.
How much debt does China SXT Pharmaceuticals have?
China SXT Pharmaceuticals had total debt of $1.1 million at the end of fiscal 2026, a debt-to-equity ratio of 0.04 and more cash than debt.
What is China SXT Pharmaceuticals's current ratio?
China SXT Pharmaceuticals's current ratio was 7.93 at the end of fiscal 2026: current assets were 7.93 times current liabilities.